Literature DB >> 16410020

Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat.

Heather J Daykin1, Sharelle A Sturgeon, Catherine Jones, Christine E Wright.   

Abstract

INTRODUCTION: Many antithrombotic drugs may have a deleterious effect on normal haemostasis leading to bleeding complications. The aim of this study was to determine if sub-therapeutic (low) doses of antithrombotic agents, when administered in combination, have enhanced efficacy without augmentation of bleeding time.
MATERIALS AND METHODS: The antithrombotic effects of i.v. aspirin (4-30 mg/kg), heparin (100-500 U/kg), enoxaparin (4-30 mg/kg) and clopidogrel (10-20 mg/kg) were studied in a rat Folts-like preparation of carotid arterial thrombosis. The frequency of cyclic flow reductions (CFRs; indicating occlusive thrombus formation) and bleeding time were measured. Drug doses that were singly ineffective at preventing occlusive thrombus formation were tested in the following combinations: aspirin (10 mg/kg) with heparin (250 U/kg); aspirin (4 mg/kg) with enoxaparin (4 mg/kg); and aspirin (10 mg/kg) with clopidogrel (10 mg/kg).
RESULTS: Control period (pretreatment) CFRs were not significantly different between groups; average 7.0+/-0.3 CFRs/30 min (n=64). Tail bleeding time before drug(s) was 3.1+/-0.1 min (n=86). When administered alone, aspirin (4-30 mg/kg), heparin (250 U/kg) or enoxaparin (4 mg/kg) had no effect on CFRs or bleeding time. Heparin (500 U/kg), enoxaparin (10 and 30 mg/kg) and clopidogrel (20 mg/kg) significantly decreased CFRs. Single administration of heparin (500 U/kg) or enoxaparin (30 mg/kg) increased bleeding time by 4- or 11-fold. When co-administered, aspirin 10 mg/kg and heparin 250 U/kg decreased CFRs, but also increased bleeding time by 11-fold. However, combination of aspirin and enoxaparin (4 mg/kg each), or aspirin and clopidogrel (10 mg/kg each), decreased CFRs with no effect on bleeding.
CONCLUSIONS: In a preparation of arterial thrombosis in the rat, combinations of sub-efficacious (low) doses of aspirin with enoxaparin or clopidogrel inhibited thrombus formation without augmenting bleeding time. However, low-dose aspirin combined with heparin, whilst inhibiting thrombus formation, exacerbated bleeding time. If these findings translate into the clinic, the use of effective low-dose combinations may have therapeutic advantages.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16410020     DOI: 10.1016/j.thromres.2005.11.015

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  Adaptation of a photochemical method to initiate recurrent platelet-mediated thrombosis in small animals.

Authors:  Karin Przyklenk; Peter Whittaker
Journal:  Lasers Med Sci       Date:  2007-03       Impact factor: 3.161

2.  Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury.

Authors:  Xiaowen Tu; Xiangmei Chen; Yuansheng Xie; Suozhu Shi; Jianzhong Wang; Yunshuang Chen; Jianjun Li
Journal:  J Am Soc Nephrol       Date:  2007-11-28       Impact factor: 10.121

3.  Glomerular capillary hemorrhage induced in rats by diagnostic ultrasound with gas-body contrast agent produces intratubular obstruction.

Authors:  Douglas L Miller; Chunyan Dou; Roger C Wiggins
Journal:  Ultrasound Med Biol       Date:  2009-01-18       Impact factor: 2.998

4.  Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.

Authors:  Pancras C Wong; Earl J Crain; Carol A Watson; Ruth R Wexler; Patrick Y S Lam; Mimi L Quan; Robert M Knabb
Journal:  J Thromb Thrombolysis       Date:  2007-02-24       Impact factor: 5.221

5.  Absence of exaggerated pharmacology by recombinant ADAMTS13 in the rat and monkey.

Authors:  Paolo Rossato; Helmut Glantschnig; Peter Leidenmühler; Alexandra Kopic; Tanja Ruthsatz; Bernhard Majer; Maria Schuster; Friedrich Scheiflinger; Werner Höllriegl
Journal:  Blood Coagul Fibrinolysis       Date:  2022-01-01       Impact factor: 1.061

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.